Our mission is to revolutionize knowledge of Alzheimer’s disease.

The Accelerating Medicines Partnership® (AMP®) Program Alzheimer’s disease (AMP AD) was the first stage of a precompetitive partnership among government, industry and nonprofit organizations that focused on discovering novel, clinically relevant therapeutic targets, and on developing biomarkers to help validate existing therapeutic targets for Alzheimer’s disease.

This multisector partnership, managed by the Foundation for the NIH from 2014-2022, focused on providing a data-driven approach for identification and validation of biomarkers and disease-relevant targets that will lead to increased clinical trial success.

Results + Accomplishments

  • Generated rich, human, multi-omic data, which has been made available to >3000 users to date (60% academia / 40% industry).

  • Established new mechanistic disease insights on role of the genome, proteome, metabolome, and microbiome.

  • Increased the availability of molecular network models of disease pathways.

  • Developed phenotype animal models and evaluated them relative to human molecular networks.

  • Identified 542 unique targets and made them available through the Agora Platform, along with supporting evidence and extensive druggability information.

  • Completed experimental validation for over 20 candidate targets.

Learn More

A Public Health Crisis

Alzheimer’s disease is a type of dementia that affects the brain, particularly areas related to memory, thinking, and behavior. It is a progressive condition, which means that symptoms worsen over time, and is projected to affect approximately 14 million people by the year 2060.

Alzheimer’s disease is caused by the buildup of abnormal protein clumps and tangles in the brain, which damage and eventually kill brain cells. In the early stages of Alzheimer’s, a person may experience forgetfulness and difficulty with planning or problem-solving. This leads to a progressive loss of cognitive functions, and symptoms worsen and interfere with daily life and activities.

Deeper Understanding of Disease Drivers

Alzheimer’s disease drug candidates have had a high failure rate in end-stage clinical trials. Developing a deeper understanding of the disease drivers is crucial to the success of these trials. AMP AD has made significant contributions to this effort through a large project focused on target discovery and preclinical validation. By integrating and sharing the analysis of large-scale molecular data from human brain samples, AMP AD rapidly identified novel therapeutic targets.

In addition, AMP AD has identified biomarkers that could be used to track responsiveness to treatment and/or disease progression. This includes exploring the utility of tau imaging and novel fluid biomarkers. These findings could potentially improve diagnosis, aid in the development of new therapies, and ultimately improve outcomes for those affected by Alzheimer’s disease. These efforts continue through the AMP AD 2.0 project.

Partners

Private Sector Partners
NP-partner
NP-partner
NP-partner
NP-partner
NP-partner
NP-partner
NP-partner
NP-partner
NP-partner
Public Sector Partners
NP-partner
NP-partner
NP-partner

Data Portals

AMP AD Knowledge Portal

Discover and download Alzheimer’s disease data, analyses, and tools from AMP AD.

Learn More
AMP AD Agora Platform

Agora is an open-source platform, created to provide curated AMP AD verified systems biology analyses showing which genes are associated with Alzheimer’s disease.

Learn More

News + Publications

News

October 1, 2019
NIH-funded translational research centers to speed, diversify Alzheimer’s drug discovery
NIA Press Release

Publications

October 17, 2021
Bile acids targeted metabolomics and medication classification data in the ADNI1 and ADNIGO/2 cohorts
Scientific Data
November 20, 2018
Generation and quality control of lipidomics data for the Alzheimer’s disease neuroimaging initiative cohort
Scientific Data
September 11, 2018
The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer’s disease
Scientific Data
August 7, 2018
A multi-omic atlas of the human frontal cortex for aging and Alzheimer’s disease research
Scientific Data
March 13, 2018
Global quantitative analysis of the human brain proteome in Alzheimer’s and Parkinson’s Disease
Scientific Data
October 11, 2016
Human whole genome genotype and transcriptome data for Alzheimer’s and other neurodegenerative diseases
Scientific Data
Contact
Francesca Cignarella, Ph.D.

Project Manager, Translational Science Neuroscience

[email protected]

Donate

Donate to the FNIH today to support medical research that saves lives

Partner With Us

Work with the FNIH to accelerate medical breakthroughs for patients